Algert Global LLC Has $625,000 Holdings in LeMaitre Vascular, Inc. $LMAT

Key Points

• Algert Global LLC increased its stake in LeMaitre Vascular, Inc. by 111.5%, holding shares worth $625,000 after acquiring an additional 3,930 shares in the first quarter.
• Insider trading activity included Director Bridget A. Ross selling 2,500 shares for approximately $235,000, indicating a 46.16% decrease in her ownership.
• LeMaitre Vascular recently reported a quarterly EPS of $0.60, beating estimates, and announced a dividend of $0.20 per share to be paid on September 4th.

Algert Global LLC grew its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 111.5% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,454 shares of the medical instruments supplier's stock after purchasing an additional 3,930 shares during the quarter. Algert Global LLC's holdings in LeMaitre Vascular were worth $625,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of LMAT. Opal Wealth Advisors LLC bought a new position in shares of LeMaitre Vascular in the first quarter valued at approximately $26,000. NBC Securities Inc. bought a new position in shares of LeMaitre Vascular in the first quarter valued at approximately $36,000. US Bancorp DE lifted its holdings in shares of LeMaitre Vascular by 36.0% in the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock valued at $117,000 after purchasing an additional 368 shares in the last quarter. Canada Pension Plan Investment Board lifted its holdings in shares of LeMaitre Vascular by 112.5% in the fourth quarter. Canada Pension Plan Investment Board now owns 1,700 shares of the medical instruments supplier's stock valued at $157,000 after purchasing an additional 900 shares in the last quarter. Finally, Blueshift Asset Management LLC bought a new position in shares of LeMaitre Vascular in the first quarter valued at approximately $232,000. Institutional investors own 84.64% of the company's stock.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 2,500 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $94.00, for a total transaction of $235,000.00. Following the completion of the transaction, the director directly owned 2,916 shares of the company's stock, valued at approximately $274,104. This represents a 46.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John A. Roush sold 6,561 shares of the stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.55, for a total value of $607,220.55. Following the transaction, the director directly owned 2,916 shares of the company's stock, valued at approximately $269,875.80. This trade represents a 69.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 120,815 shares of company stock valued at $11,280,206 in the last three months. 9.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on LMAT. Cantor Fitzgerald raised their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target for the company in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, LeMaitre Vascular currently has a consensus rating of "Hold" and an average target price of $97.60.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $100.33 on Friday. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of 48.70, a PEG ratio of 2.58 and a beta of 0.79. The stock has a 50 day moving average of $85.98 and a 200 day moving average of $86.41. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating analysts' consensus estimates of $0.57 by $0.03. The company had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.LeMaitre Vascular's revenue was up 15.0% on a year-over-year basis. During the same period last year, the business posted $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st will be issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Thursday, August 21st. LeMaitre Vascular's dividend payout ratio is 38.83%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.